davunetide and Craniocerebral-Trauma

davunetide has been researched along with Craniocerebral-Trauma* in 1 studies

Other Studies

1 other study(ies) available for davunetide and Craniocerebral-Trauma

Article	Year
Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults. Neuroreport, 2003, Mar-03, Volume: 14, Issue:3 The prophylactic neuroprotective effects of NAP, a femtomolar-acting neuroprotective peptide were tested in a mouse model of head trauma. NAP was injected for the first 3 weeks of life and head injury was initiated at 4 months. After trauma, mice were tested for their performance by evaluating damaged motor ability, balance and alertness. Comparison of the performance 1 h and 1 week after injury indicated that NAP treatment resulted in faster and enhanced recovery. In a 5-day Morris water maze test with mice suffering moderate to severe injuries, only the NAP-treated group learned to find the hidden platform in the maze. Furthermore, NAP treatment resulted in decreased mRNA expression of the inflammation marker, Mac-1. Thus, a potentially new prophylactic treatment against neurodegeneration is suggested. Topics: Aging; Animals; Animals, Newborn; Craniocerebral Trauma; Injections, Subcutaneous; Learning Disabilities; Male; Maze Learning; Memory Disorders; Mice; Neuroprotective Agents; Oligopeptides; Recovery of Function; Trauma Severity Indices; Wounds, Nonpenetrating	2003

Article

Year

Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults.

Neuroreport, 2003, Mar-03, Volume: 14, Issue:3

The prophylactic neuroprotective effects of NAP, a femtomolar-acting neuroprotective peptide were tested in a mouse model of head trauma. NAP was injected for the first 3 weeks of life and head injury was initiated at 4 months. After trauma, mice were tested for their performance by evaluating damaged motor ability, balance and alertness. Comparison of the performance 1 h and 1 week after injury indicated that NAP treatment resulted in faster and enhanced recovery. In a 5-day Morris water maze test with mice suffering moderate to severe injuries, only the NAP-treated group learned to find the hidden platform in the maze. Furthermore, NAP treatment resulted in decreased mRNA expression of the inflammation marker, Mac-1. Thus, a potentially new prophylactic treatment against neurodegeneration is suggested.

Topics: Aging; Animals; Animals, Newborn; Craniocerebral Trauma; Injections, Subcutaneous; Learning Disabilities; Male; Maze Learning; Memory Disorders; Mice; Neuroprotective Agents; Oligopeptides; Recovery of Function; Trauma Severity Indices; Wounds, Nonpenetrating

2003